StockUS listing USLKFTNASDAQHealthcareQuality Compounder

Lakefront Biotherapeutics NV(LKFT) Stock Analysis | Healthcare

USD --+0.00%
Reward66High
Risk19Low
75%Data
Strong 60% profit margin · Revenue down 82% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.18Bn
Reward Ratingⓘ66 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ19 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LKFT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Lakefront Biotherapeutics NV?

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

AI Brief Pro

The brief on Lakefront Biotherapeutics NV

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Lakefront Biotherapeutics NV?

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.18B, and a P/E ratio of 2.4x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (66)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio2.3895
Beta0.012
Insider Activity
12M windowNo data
No insider activity data available for this ticker.